Architecture Day 2025 Draws 15,000 Visitors Across North Rhine-Westphalia, Showcasing Diversity and Social Impact in Design
SHERIDAN, WYOMING – July 2, 2025 – The 30th edition of North Rhine-Westphalia’s Architecture Day (Tag der Architektur) captivated around 15,000 visitors last weekend as architecture enthusiasts explored 156 innovative and renovated projects spread across 80 cities and towns, underscoring the enduring societal significance of design in Germany’s most populous state.
LINAK Sets New Standards in Adjustable Furniture at interzum 2025 with EXPERIENCE™ Series and Innovative Comfort Solutions
SHERIDAN, WYOMING – July 2, 2025 – LINAK has unveiled a powerful lineup of electric actuator technologies and customization options at interzum 2025 in Cologne, positioning itself at the forefront of ergonomic and branding-driven furniture innovation for the contract and residential markets.
Introducing the EXPERIENCE™ Series: Faster, Quieter, and Built to Last
LINAK Unveils Plug-and-Play LC3 IC Lifting Column to Streamline Heavy-Duty Industrial Automation
SHERIDAN, WYOMING – July 2, 2025 – LINAK has introduced its LC3 IC electric lifting column, a pre-tested, ready-to-use solution engineered to simplify demanding lifting tasks in industrial automation projects. This launch provides machinery manufacturers with a proven, instantly deployable alternative to custom-built lifting mechanisms, helping reduce engineering complexity, shorten project timelines, and improve ROI.
A Turnkey Solution for Heavy Lifting Applications
Sid Lee Architecture Transforms Place Ville Marie HQ into Dynamic Urban Biosquare
SHERIDAN, WYOMING – July 2, 2025 – Sid Lee Architecture has unveiled its redesigned headquarters in Montreal’s Place Ville Marie, a project that embodies a bold vision for integrating workplace design with urban vitality. The transformation, known as the “Biosquare,” aims to reinvigorate Montreal’s downtown core while redefining how creative professionals engage with their environment.
A Strategic Hub for Creative Collaboration
BHB GardenSummit 2025: Industry Experts Address Opportunities, Challenges, and the Future of the Green Market
SHERIDAN, WYOMING – July 1, 2025 – The 10th BHB-GardenSummit in Cologne once again demonstrated its commitment to sharing strategies and trends that can strengthen the garden retail sector, bringing together over 110 industry leaders despite notable absences among exhibitors and experts.
Keynote Emphasizes Importance of Green Assortments
CAR T REMS Removal Poised to Expand Market and Democratize Access
SHERIDAN, WYOMING – July 1, 2025 – The U.S. Food and Drug Administration’s recent decision to remove Risk Evaluation and Mitigation Strategies (REMS) from approved CAR T cell therapies marks a pivotal shift that could reshape access to these potentially curative treatments and drive significant market expansion across the cell and gene therapy industry.
FDA Greenlights Neurogene’s ‘Best-Case Scenario’ Pivotal Trial Design for Rett Syndrome Gene Therapy
SHERIDAN, WYOMING – July 1, 2025 – Neurogene has reached alignment with the FDA regarding the design of a registrational study for the investigational gene therapy NGN-401 for Rett Syndrome, enabling the company to convert its current Phase I/II study into a pivotal trial—a milestone that analysts describe as the “best-case scenario.”
Argenx and UNP Forge $1.5B Macrocyclic Peptide Alliance to Target ‘Undruggable’ Diseases
SHERIDAN, WYOMING – July 1, 2025 – Argenx has taken a decisive step to diversify its pipeline beyond its flagship FcRn blocker, signing a multi-target research agreement with Unnatural Products, Inc. (UNP) that could exceed $1.5 billion. The deal aims to harness UNP’s proprietary macrocyclic peptide technology to develop oral therapies for disease targets historically deemed “undruggable,” marking the largest licensing transaction to date in the macrocyclic peptide space.
Strategic Expansion Beyond FcRn Blockade
Protagonist Targets Obesity Market with Flexible Oral Triple-G Agonist PN-477
SHERIDAN, WYOMING – July 1, 2025 – Protagonist Therapeutics has stepped into the fiercely competitive obesity treatment landscape by nominating PN-477, an innovative triple agonist therapy, aiming to deliver flexibility in dosing and a differentiated profile among next-generation anti-obesity drugs.